Further structural changes as Takeda focuses R&D strategy

15 May 2017
takeda_big

Japanese drugmaker Takeda Pharmaceutical (TSE: 4502) has announced that it has hived off part of its pharmaceutical R&D business to form a new wholly-owned subsidiary.

In addition, the company has finished a deal to transfer part of its pharmaceutical sciences businesses to privately-held Bushu Pharmaceuticals.

Takeda says the purpose of the structural reorganization is to accelerate changes to its research and development (R&D) program, by focusing on three key therapeutic areas – oncology, gastroenterology and central nervous system, plus vaccines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical